Sanjiban Chakrabarty

Manipal School of Life Sciences

Dr. Sanjiban Chakrabarty is an Assistant Professor at the Department of Cell and Molecular Biology, Manipal School of Life Sciences, MAHE. Trained in biochemistry. He obtained his PhD in human genetics from MAHE in 2013. Trained in biochemistry, he obtained his PhD in human genetics from MAHE in 2013. Dr. Sanjiban has previously identified a set of methylation signatures that correlates with disease progression, HR status and menopausal status in a breast cancer cohort in collaboration with Philips Research India (US patent, US20130102483A1). Previously, his group have identified recurrent mutations in ARID1A, SMARCA4, MLL2, SETD2 and TET2 genes involved in histone modification, chromatin remodeling and DNA damage response and chromosomal aberration in an Indian cohort of UC associated colorectal carcinoma (UC-CRC) patients (Chakrabarty et al, 2017, Shivakumar BM et al., 2016, 2015, Indian Patent). During his postdoctoral training, he has developed a microfluidic organ-on-chip (OoC) technology and demonstrated its application in breast cancer patient therapy response. The study was performed at Dr. Dik van Gent’s lab (Erasmus MC), in collaboration with Delft University of Technology and Dr. Jos Jonkers, Netherlands Cancer Institute, The Netherlands which was funded by the Dutch Cancer Foundation (KWF). Dr. Sanjiban has experience in working with panel of patient-derived xenograft (PDX) models of BRCA1-proficient and BRCA1-deficient triple-negative breast cancer to study cisplatin and PARPi response in organ-on-chip platforms. Dr. Chakrabarty was instrumental in setting up organ-on-chip technology to study breast cancer chemo sensitivity in platinum sensitive and platinum resistant breast PDX tumor models and patient derived tumor tissue slice culture for platinum and PARPi treatment response. During his postdoctoral training at Erasmus Medical Center, The Netherlands, he has identified novel LIG3 mutation and its functional association with mtDNA repair disorder in patients (Chakrabarty S, et al Brain, 2021). He has published 37 papers in international journals and 2 patents to his credit.